A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma
- Authors:
- Published online on: August 14, 2020 https://doi.org/10.3892/or.2020.7735
- Pages: 1949-1960
-
Copyright : © Takei et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Abstract
Introduction
Oral cancers account for about 2% of all cancer cases diagnosed worldwide (1). More than 350,000 individuals are diagnosed with oral cancer every year, and oral cancers prove fatal for approximately 170,000 of these people. Major risk factors for oral cancer include the use of alcohol and tobacco (2). Although decreased drinking and smoking have resulted in a decline in the incidence of oral cancer, recent studies have reported an increase in the number of young patients diagnosed with these diseases (3,4).
CD44 is known to be expressed in many cell types, including epithelial cells, fibroblasts, endothelial cells, and leukocytes (5). CD44 plays important roles in cell proliferation, adhesion, and migration (6). The CD44 gene consists of 20 exons (7). The smallest isoform is the standard form of CD44 (CD44s), which possesses 10 exons; other possible isoforms are categorized as CD44 variants (CD44v), which are generated by alternatively spliced transcripts (8). Post-translational modifications such as N- and O-glycosylation and heparan sulfate modification also augment the diversity of CD44 (9,10). Both CD44s and CD44v are overexpressed in many cancers; however, a pattern of expression remains to be elucidated.
One of the CD44 variants, CD44v6, was first identified as contributing to cancer metastasis, and CD44v6-specific monoclonal antibodies (mAbs) were found to inhibit metastasis of rat pancreatic cancers (11,12). Some CD44v6 isoforms act as co-receptors for receptor tyrosine kinases (RTKs) such as MET and vascular endothelial growth factor receptor (VEGFR)-2 (13–15). The transfection of CD44v4-7 cDNA confers a metastatic phenotype in non-metastatic cells (16). Another CD44 variant, CD44v3, binds to several heparan sulfate-binding growth factors such as fibroblast growth factors (FGFs) and heparin-binding epidermal growth factor (HB-EGF), and induces tumor progression (17,18). Several CD44 variants were also reported as prognostic markers in head and neck, lung, colorectal, breast, and hepatocellular cancers (19–23).
Many mAbs have been developed to target CD44 (24–26). mAbs that neutralize contact between hyaluronic acid and CD44 have been shown to inhibit anchorage-independent growth of murine mammary carcinoma cells and human colon carcinoma cells (24). Anti-CD44 mAbs were also found to exhibit significant antitumor activity in mouse xenograft models of human cancers (25,26). Previously, we established clone C44Mab-5 (IgG1, kappa) using Cell-Based Immunization and Screening (CBIS) (27). C44Mab-5 recognized both CD44s and CD44v isoforms, and demonstrated high sensitivity for flow cytometry and immunohistochemical analysis in oral cancers. Because the IgG1 subclass of C44Mab-5 lacks antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), antitumor activity of C44Mab-5 could not be determined.
In this study, we converted the IgG1 subclass C44Mab-5 into a mouse IgG2a subclass mAb, 5-mG2a, and further produced a defucosylated version, 5-mG2a-f, using FUT8-deficient ExpiCHO-S cells (28). We then investigated whether 5-mG2a-f exhibited ADCC, CDC and antitumor activities against oral cancers.
Materials and methods
Cell lines
Oral squamous carcinoma cell lines including HSC-2 (oral cavity) and SAS (tongue) were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB; Osaka, Japan). Chinese hamster ovary (CHO)-K1 was obtained from the American Type Culture Collection (ATCC). CD44v3-10 plus N-terminal PA16 tag-overexpressed CHO-K1 (CHO/PA16-CD44v3-10) was generated by transfection of pCAG/PA16-CD44v3-10 to CHO-K1 cells using the Neon Transfection System (Thermo Fisher Scientific, Inc.). The PA16 tag consists of 16 amino acids (GLEGGVAMPGAEDDVV) (27). HSC-2 and SAS cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Nacalai Tesque, Inc.), and CHO-K1 and CHO/PA16-CD44v3-10 were cultured in RPMI-1640 medium (Nacalai Tesque, Inc.), supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific Inc.), 100 units/ml of penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B (Nacalai Tesque, Inc.) at 37°C in a humidified atmosphere containing 5% CO2.
Antibodies
Mouse anti-CD44s mAb C44Mab-5 (IgG1, kappa) was developed as previously described (27). Mouse IgG was purchased from Sigma-Aldrich Corp. (Merck KGaA). To generate recombinant C44Mab-5 (recC44Mab-5), cDNAs of C44Mab-5 heavy and light chains were subcloned into pCAG-Neo and pCAG-Ble vectors (FUJIFILM Wako Pure Chemical Corporation), respectively. To generate 5-mG2a-f, appropriate VH cDNA of mouse C44Mab-5 and CH of mouse IgG2a were subcloned into pCAG-Neo vector, and light chain of C44Mab-5 was subcloned into pCAG-Ble vector. Vectors were transfected into ExpiCHO-S or BINDS-09 (FUT8-deficient ExpiCHO-S cells) using the ExpiCHO Expression System (28). recC44Mab-5 and 5-mG2a-f were purified using Protein G-Sepharose (GE Healthcare Bio-Sciences).
Animals
All animal experiments were performed in accordance with relevant guidelines (e.g. ARRIVE guidelines) and regulations (e.g. 3R regulations) to minimize animal suffering and distress in the laboratory (29,30). Seventy female BALB/c nude mice (6 weeks old, 15–18 g) were purchased from Charles River (Kanagawa, Japan). Animal studies for ADCC and antitumor activity were approved by the Institutional Committee for Experiments of the Institute of Microbial Chemistry (permit number: 2020-003). Mice were maintained in a pathogen-free environment (23±2°C, 55±5% humidity) on 11 h light/13 h dark cycle with food and water supplied ad libitum during the experimental period. Mice were monitored for health and weight every 1 or 5 days. Experiment duration was three weeks. A bodyweight loss exceeding 25% and a maximum tumor size exceeding 3,000 mm3 were identified as humane endpoints. Mice were euthanized by cervical dislocation, and the death was verified by respiratory arrest and cardiac arrest.
Enzyme-linked immunosorbent assay (ELISA)
C44Mab-5 and 5-mG2a-f were immobilized on Nunc Maxisorp 96-well immunoplates (Thermo Fisher Scientific Inc.) at 1 µg/ml for 30 min. After blocking using SuperBlock buffer (Thermo Fisher Scientific Inc.) containing 0.5 mM CaCl2, the plates were incubated with biotin-labeled lectins, such as Aleuria aurantia lectin (AAL; Vector Laboratories), Pholiota squarrosa lectin (PhoSL; J-OIL MILLS, Inc.) (31), and concanavalin A (ConA; Vector Laboratories), followed by 1:3,000 diluted peroxidase-conjugated streptavidin (Agilent Technologies). The enzymatic reaction was produced using a 1-Step Ultra TMB-ELISA (Thermo Fisher Scientific Inc.). The optical density was measured at 655 nm using an iMark microplate reader (Bio-Rad Laboratories, Inc.).
Flow cytometry
Cells were harvested by brief exposure to 0.25% trypsin/1 mM ethylenediaminetetraacetic acid (EDTA; Nacalai Tesque, Inc.). After washing with 0.1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), cells were treated with primary mAbs for 30 min at 4°C and subsequently with Alexa Fluor 488-conjugated anti-mouse IgG (1:1,000; Cell Signaling Technology, Inc.). Fluorescence microscopy data were collected using an EC800 Cell Analyzer (Sony Corp.).
Immunohistochemical analyses
Histologic sections (4-µm thick) of an oral cancer tissue microarray (catalogue number: OR481; US Biomax Inc.) were directly autoclaved in citrate buffer (pH 6.0; Agilent Technologies Inc.) for 20 min. Sections were then incubated with 1 µg/ml primary mAbs for 1 h at room temperature and treated using an Envision+ Kit (Agilent Technologies) for 30 min. Color was developed using 3,3′-diaminobenzidine tetrahydrochloride (DAB; Agilent Technologies Inc.) for 2 min, and sections were then counterstained with hematoxylin (FUJIFILM Wako Pure Chemical Corporation). Hematoxylin and eosin (H&E) staining (FUJIFILM Wako Pure Chemical Corporation) was performed using consecutive tissue sections. Leica DMD108 (Leica Microsystems GmbH) was used to examine the sections and obtain images.
Determination of the binding affinity
Cells were suspended in 100 µl of serially diluted mAbs (0.3 ng/ml-5 µg/ml), followed by the addition of Alexa Fluor 488-conjugated anti-mouse IgG (1:200; Cell Signaling Technology, Inc.). Fluorescence microscopy data were collected using an EC800 Cell Analyzer (Sony Corp.). The dissociation constant (KD) was calculated by fitting binding isotherms to built-in one-site binding models in GraphPad PRISM 8 (GraphPad Software, Inc.).
Western blot analysis
Cell lysates (10 µg) were boiled in sodium dodecyl sulfate (SDS) sample buffer (Nacalai Tesque, Inc.). Proteins were separated on 5–20% polyacrylamide gels (FUJIFILM Wako Pure Chemical Corporation) and transferred onto polyvinylidene difluoride (PVDF) membranes (Merck KGaA). After blocking with 4% skim milk (Nacalai Tesque, Inc.) in PBS with 0.05% Tween 20, the membranes were incubated with 10 µg/ml of an anti-CD44 mAb [clone C44Mab-46 (mouse IgG1, kappa)]; available from Antibody Bank of Tohoku University (ABTU; Miyagi, Japan); http://www.med-tohoku-antibody.com/topics/001_paper_antibody_PDIS.htm#antiCD44) or 1 µg/ml of anti-β-actin (clone AC-15; cat. no. A5441; Sigma-Aldrich Corp.; Merck KGaA). This was followed by incubation with peroxidase-conjugated anti-mouse immunoglobulins (Agilent Technologies Inc.). Finally, protein bands were detected with ImmunoStar LD (FUJIFILM Wako Pure Chemical Corporation) using a Sayaca-Imager (DRC Co., Ltd.).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNAs were prepared from cell lines using an RNeasy Mini Prep Kit (Qiagen Inc.). The initial cDNA strand was synthesized using SuperScript IV Reverse Transcriptase (Thermo Fisher Scientific, Inc.) by priming nine random oligomers and an oligo(dT) primer according to the manufacturer's instructions. We performed 35 cycles of PCR for amplification using HotStarTaq DNA Polymerase (Qiagen Inc.) with 0.2 µM of primer sets: Human CD44 sense (5′-GAAAGGAGCAGCACTTCAGG-3′), human CD44 antisense (5′-ACTGCAATGCAAACTGCAAGC-3′), GAPDH sense (5′-CAATGACCCCTTCATTGACC-3′), and GAPDH antisense (5′-GTCTTCTGGGTGGCAGTGAT-3′).
ADCC
Six six-week-old female BALB/c nude mice were purchased from Charles River (Kanagawa, Japan). After euthanization by cervical dislocation, spleens were removed aseptically and single-cell suspensions obtained by forcing spleen tissues through a sterile cell strainer (352360, BD Falcon, Corning, Inc.) using a syringe. Erythrocytes were lysed with a 10-sec exposure to ice-cold distilled water. Splenocytes were washed with DMEM and resuspended in DMEM with 10% FBS and used as effector cells. Target cells were labeled with 10-µg/ml Calcein AM (Thermo Fisher Scientific, Inc.) and resuspended in the same medium. The target cells (2×104 cells/well) were plated in 96-well plates and mixed with effector cells, anti-CD44s antibodies, or control IgG (mouse IgG2a) (Sigma-Aldrich Corp.; Merck KGaA). After a 5-h incubation, the Calcein AM release of supernatant from each well was measured. Fluorescence intensity was determined using a microplate reader (Power Scan HT) (BioTek Instruments) with an excitation wavelength of 485 nm and an emission wavelength of 538 nm. Cytolytic activity (as % of lysis) was calculated using the equation: % lysis=(E-S)/(M-S) ×100, where E is the fluorescence of the combined target and effector cells, S is the spontaneous fluorescence of the target cells only, and M is the maximum fluorescence measured after lysing all cells with a buffer containing 0.5% Triton X-100, 10 mM Tris-HCl (pH 7.4), and 10 mM of EDTA.
CDC
Cells in DMEM supplemented with 10% FBS were plated in 96-well plates (2×104 cells/well), and incubated for 5 h at 37°C with either anti-CD44s antibodies or control IgG (mouse IgG2a) (Sigma-Aldrich Corp.; Merck KGaA) and 10% rabbit complement (Low-Tox-M Rabbit Complement; Cedarlane Laboratories). To assess cell viability, an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; inner salt] assay was performed using a CellTiter 96®AQueous assay kit (Promega Corp.).
3D cell proliferation assay
3D cell proliferation was measured with the CellTiter-Glo® 3D cell viability assay (Promega Corp.) according to the manufacturer's instructions. Briefly, the cells were plated (2,000 cells/100 µl/well) in triplicate in 96-well ultra low attachment plates (Corning Inc.) with PBS or 100 µg/ml of mouse IgG2a and an anti-CD44 mAb (5-mG2a-f) in DMEM containing 10% FBS. The cell viability was measured after 48 h of incubation. The CellTiter-Glo® 3D reagent was added into wells in a 1:1 dilution (100 µl volume in well:100 µl of reagent) and then the plates were shaken for 5 min on an orbital shaker and incubated at room temperature for an additional 25 min. The luminescent signal was read using an EnSpire multi-plate reader (Perkin Elmer). Images were taken using an Evolution MP camera (Media Cybernetics). The proliferation rate was calculated relative to the control (PBS was added instead of the antibodies).
Antitumor activity of 5-mG2a-f in the xenografts of oral cancers
Sixty-four six-week-old female BALB/c nude mice were purchased from Charles River (Kanagawa, Japan) and used at 10 weeks of age. HSC-2 and SAS cells (0.3 ml of 1.33×108 cells/ml in DMEM) were mixed with 0.5 ml BD Matrigel Matrix Growth Factor Reduced (BD Biosciences). One hundred microliters of this suspension (5×106 cells) was injected subcutaneously into the left flank. After day 1 (protocol-1) or day 7 (protocol-2), 100 µg of 5-mG2a-f and control mouse IgG (Sigma-Aldrich Corp.; Merck KGaA) in 100 µl PBS were injected intraperitoneally (i.p.) into treated and control mice, respectively. Additional antibodies were then injected on days 7 and 14 (protocol-1) or on days 14 and 21 (protocol-2). Nineteen days (protocol-1) or 27 days (protocol-2) after cell implantation, all mice were euthanized by cervical dislocation and tumor diameters and volumes were determined as previously described (32).
Statistical analyses
All data are expressed as mean ± standard error of the mean (SEM). Statistical analysis was carried out using ANOVA following Tukey-Kramer's test for ADCC and CDC. Sidak's multiple comparisons test was used for tumor volume and mouse weight, or Welch's t test for tumor weight and 3D cell proliferation assay using GraphPad Prism 7 (GraphPad Software, Inc.). P<0.05 was adopted as a level of statistical significance.
Results
Production and characterization of 5-mG2a-f, a core-fucose-deficient mouse IgG2a-type anti-CD44 antibody
As mouse IgG2a possesses high ADCC and CDC activities (33), we first produced a mouse IgG2a version of mouse IgG1 C44Mab-5 by subcloning appropriate VH cDNA of C44Mab-5 and CH of mouse IgG2a into pCAG-Neo vector, and light chain of C44Mab-5 into pCAG-Ble vector. This IgG2a-type of C44Mab-5 is henceforth referred to as 5-mG2a. We additionally produced a core-fucose-deficient type of 5-mG2a, henceforth referred to as 5-mG2a-f, using the BINDS-09 cell line (FUT8-knockout Expi-CHO-S cell line) (28). Defucosylation of 5-mG2a-f was confirmed using lectins such as Aleuria aurantia lectin (AAL, fucose binder) (34) and Pholiota squarrosa lectin (PhoSL, core fucose binder) (31). Concanavalin A (ConA, mannose binder) (35) was used as a control. Both C44Mab-5 and 5-mG2a-f were detected using ConA (Fig. 1A). C44Mab-5, but not 5-mG2a-f, was detected using AAL (Fig. 1B) or PhoSL (Fig. 1C), indicating that 5-mG2a-f was defucosylated.
We examined the sensitivity of 5-mG2a-f in CHO cells expressing CD44v3-10 plus N-terminal PA16 tag (CHO/PA16-CD44v3-10) and in oral squamous cell carcinoma (OSCC) cell lines (SAS and HSC-2) using flow cytometry. Both C44Mab-5 and 5-mG2a-f reacted with CHO/PA16-CD44v3-10 cells (Fig. 2A), but not with CHO-K1 cells (Fig. 2B). Both C44Mab-5 and 5-mG2a-f reacted with SAS cells (Fig. 2C) and HSC-2 cells (Fig. 2D), indicating that both mAbs showed high sensitivity against SAS and HSC-2 cells.
As shown in Fig. S1A, CD44 was not detected by an anti-CD44s mAb (C44Mab-46) in both SAS and HSC-2 cells presumably because the CD44 expression level in those cells might be low for the detection in western blot analysis. Then, we performed RT-PCR analysis for detection of CD44. As shown in Fig. S1B, the multiple bands of CD44v were detected in SAS and HSC-2 cells using PCR, indicating that CD44v is expressed in SAS and HSC-2 cells.
Next, we performed immunohistochemical analysis on oral cancer cell lines. Representative images are shown in Fig. 3. Both C44Mab-5 (Fig. 3A and B) and 5-mG2a-f (Fig. 3C and D) stained the plasma membrane of oral cancer cells. The sensitivity of 5-mG2a-f was similar with that of C44Mab-5. Both C44Mab-5 and 5-mG2a-f stained 33/38 cases (86.8%) of OSCCs of the tissue microarray. Hematoxylin & eosin (H&E) staining of consecutive tissue sections of OSCC is shown in Fig. 3E and F.
We performed a kinetic analysis of the interactions of recC44Mab-5 and 5-mG2a-f with SAS and HSC-2 oral cancer cell lines using flow cytometry. As shown in Fig. 4A, the dissociation constant (KD) for recC44Mab-5 in SAS cells was 2.4×10−10 M. In contrast, the KD for 5-mG2a-f in SAS cells was 2.8×10−10 M (Fig. 4A). The binding affinity of 5-mG2a-f in SAS cells was very similar to that of recC44Mab-5. Likewise, the KD for recC44Mab-5 against HSC-2 was 2.3×10−9 M (Fig. 4B). In contrast, the KD for 5-mG2a-f in HSC-2 cells was 2.6×10−9 M (Fig. 4B). The binding affinity of 5-mG2a-f in HSC-2 cells was very similar to that of recC44Mab-5. The binding affinity of 5-mG2a-f in SAS was 9.3-fold higher than that against HSC-2.
ADCC and CDC activities of 5-mG2a-f in oral cancer cell lines
Because the mouse IgG1 subclass of C44Mab-5 does not possess ADCC or CDC activities, we synthesized a mouse IgG2a subclass mAb, and further defucosylated it to augment those activities. In this study, we examined whether the developed 5-mG2a-f induced ADCC and CDC in CD44-expressing oral cancer cell lines, such as SAS and HSC-2 cells. As shown in Fig. 5A, 5-mG2a-f exhibited higher ADCC (16% cytotoxicity) in SAS cells compared with that of control PBS (3.4% cytotoxicity; P<0.01) and control mouse IgG2a treatment (4.2% cytotoxicity; P<0.01). Similarly, 5-mG2a-f exhibited higher ADCC (18% cytotoxicity) against HSC-2 cells compared with that of control PBS (3.1% cytotoxicity; P<0.01) and control mouse IgG2a treatment (5.2% cytotoxicity; P<0.01), indicating that ADCC in SAS cells is similar with that in HSC-2 cells, despite the binding affinity of 5-mG2a-f in SAS cells being 9.3-fold higher than in HSC-2 cells (Fig. 4). As shown in Fig. 5B, 5-mG2a-f exhibited slightly higher CDC (33% cytotoxicity) in SAS cells compared with control PBS (21% cytotoxicity; P<0.01) and control mouse IgG2a treatment (22% cytotoxicity; P<0.01). Similarly, 5-mG2a-f exhibited slightly higher CDC (30% cytotoxicity) in HSC-2 cells compared with control PBS (18% cytotoxicity; P<0.01) and control mouse IgG2a treatment (19% cytotoxicity; not significant). Although ADCC/CDC activities of 5-mG2a-f in oral cancer cells are not outstanding, 5-mG2a-f may exert antitumor activity against oral cancer cells in vivo.
The influence of 5-mG2a-f in oral cancer cell lines in anchorage-independent condition
Next, we investigated whether 5-mG2a-f inhibits cell growth of SAS and HSC-2 cells in anchorage-independent condition. As shown in Fig. S2A, both SAS and HSC-2 cells grew in anchorage-independent condition for 48 h. In contrast, an anti-CD44 mAb (5-mG2a-f) did not inhibit the growth of SAS or HSC-2 compared to control mouse IgG2a (Fig. S2B), indicating that 5-mG2a-f did not affect the cell growth of oral cancer cell lines in anchorage-independent condition.
Antitumor activities of 5-mG2a-f in the mouse xenografts of SAS oral cancer cells
SAS cells were subcutaneously implanted into the flanks of nude mice. In protocol-1, 5-mG2a-f (100 µg) and control mouse IgG (100 µg) were injected i.p. three times into the mice, on days 1, 7, and 14 after SAS cell injections. Tumor volume was measured on days 6, 12, 15, and 19. Tumor development was significantly reduced in the 5-mG2a-f-treated mice on days 12, 15, and 19 in comparison to the IgG-treated control mice (Fig. 6A). Tumor volume on day 19 was reduced by 27% after 5-mG2a-f treatment. Tumors from 5-mG2a-f-treated mice weighed significantly less than tumors from IgG-treated control mice (16.9% reduction, Fig. 6B). Resected tumors on day 19 are depicted in Fig. 6C. Control and 5-mG2a-f-treated SAS xenograft mice are shown on day 19 in Fig. S3A and B, respectively. Total body weights did not significantly differ between the two groups (Fig. S3C).
In protocol-2 of the SAS xenograft models, tumor formation of 16 SAS-bearing mice was observed on day 7. Then, these 16 SAS-bearing mice were divided into a 5-mG2a-f-treated group and a control group. On days 7, 14, and 21 after SAS cell injections into the mice, 5-mG2a-f (100 µg) and control mouse IgG (100 µg) were injected i.p. into the mice. Tumor formation was observed in mice in both treated and control groups. Tumor volume was measured on days 7, 12, 15, 19, 22, and 27. 5-mG2a-f-treated mice displayed significantly reduced tumor development on days 22 and 27 in comparison to IgG-treated control mice (Fig. 7A). Tumor volume reduction by 5-mG2a-f was 43% on day 27. Tumors from the 5-mG2a-f-treated mice weighed significantly less than tumors from the IgG-treated control mice (27.1% reduction, Fig. 7B). Resected tumors on day 27 are depicted in Fig. 7C. Control and 5-mG2a-f-treated SAS xenograft mice are shown on day 27 in Fig. S4A and B, respectively. Total body weights did not significantly differ between the two groups (Fig. S4C). These results indicate that 5-mG2a-f reduced the growth of SAS xenografts effectively, even when 5-mG2a-f was injected 7 days post-SAS cell injections in mice.
Antitumor activities of 5-mG2a-f in mouse xenografts of HSC-2 oral cancer cells
In a second xenograft model of oral cancers, HSC-2 cells were subcutaneously implanted into the flanks of nude mice. In protocol-1 of HSC-2 ×enograft models, 5-mG2a-f (100 µg) and control mouse IgG (100 µg) were injected i.p. three times into the mice, on days 1, 7, and 14 after HSC-2 cell injections into the mice. Tumor volume was measured on days 6, 12, 15, and 19. 5-mG2a-f-treated mice displayed significantly reduced tumor development on days 12, 15, and 19 in comparison to IgG-treated control mice (Fig. 8A). Tumor volume reduction by 5-mG2a-f was 53% on day 19. Tumors from 5-mG2a-f-treated mice weighed significantly less than HSC-2 tumors from IgG-treated control mice (44.1% reduction, Fig. 8B). Resected tumors on day 19 are depicted in Fig. 8C. Control and 5-mG2a-f-treated HSC-2 ×enograft mice are shown on day 19 in Fig. S5A and B, respectively. Total body weights did not significantly differ between the two groups (Fig. S5C).
In protocol-2 of the HSC-2 ×enograft models, tumor formation of 16 HSC-2-bearing mice was observed on day 7. Then, these 16 HSC-2-bearing mice were divided into a 5-mG2a-f-treated group and a control group. On days 7, 14, and 21 after cell injections into the mice, 5-mG2a-f (100 µg) and control mouse IgG (100 µg) were injected i.p. into the mice. Tumor volume was measured on days 7, 12, 15, 19, 22, and 27. 5-mG2a-f-treated mice displayed significantly reduced tumor development on days 22 and 27 in comparison to IgG-treated control mice (Fig. 9A). Tumor volume reduction in 5-mG2a-treated mice was 32% on day 27. Tumors from 5-mG2a-f-treated mice weighed significantly less than tumors from IgG-treated control mice (27.1% reduction, Fig. 9B). Resected tumors on day 27 are depicted in Fig. 9C. Control and 5-mG2a-f-treated HSC-2 ×enograft mice are shown on day 27 in Fig. S6A and B, respectively. Total body weights did not significantly differ between the two groups (Fig. S6C). These results indicate that 5-mG2a-f reduced the growth of HSC-2 ×enografts effectively, even when 5-mG2a-f was injected 7 days post-HSC-2 cell injections in mice.
Discussion
In the present study, we investigated whether anti-CD44 mAbs are advantageous for the treatment of oral cancers. We previously developed a sensitive and specific anti-CD44 mAb, C44Mab-5, but were unable to demonstrate antitumor activity because the IgG1 subclass does not possess ADCC/CDC activities (27). In this study, we developed this antibody into an IgG2a subclass antibody, and augmented ADCC activity using a defucosylated variant. Oral cancers comprise several histological tumor types, such as squamous cell carcinoma (SCC), adenocarcinoma, mucoepidermoid carcinoma, and adenoid cystic carcinoma. Among these, SCC accounts for over 90% of all oral cancers (36). Therefore, we used SAS and HSC-2 cell lines, which are derived from SCC, and investigated ADCC/CDC and antitumor activities.
The most effective treatment of OSCC depends upon its clinical stage. Stage-I and -II (early stages) are treated via surgery or radiotherapy alone. In contrast, stage-III and -IV (advanced stages) require a combination of surgery, radiotherapy, and chemotherapy (37). For chemotherapy of OSCCs, cisplatin is mainly used, and is often combined with docetaxel and 5-fluorouracil (38,39). Other anticancer agents, such as paclitaxel, carboplatin, and methotrexate can be also used for OSCCs (40), but effective molecular targeting drugs, such as antibody therapies, are limited.
Recently, cetuximab, a mouse-human chimeric mAb (IgG1) that targets epidermal growth factor receptor (EGFR), was approved by the Food and Drug Administration (FDA) in the USA for treatment of oral cancers (41). Cetuximab has been shown effective against locoregionally advanced head and neck cancer and recurrent or metastatic squamous cell carcinoma of the head and neck (41–43). Although advances in diagnosis and therapeutic techniques have improved the overall 5-year survival rate to 70%, the 5-year survival rate in stage IV is only 40%; therefore, further treatments must be developed (44). In our recent study, we also developed a sensitive and specific mAb (EMab-17) against EGFR, and demonstrated its ADCC/CDC and antitumor activity against SAS and HSC-2 ×enografts (32). Although we showed that EMab-17 could potentially be used for antibody-based therapy for EGFR-expressing OSCC, the difference between cetuximab and EMab-17 has not been clarified. Several studies characterizing EMab-17, including epitope mapping and signal induction in OSCC cells, are currently ongoing.
In another recent study, HER2 was shown to be expressed in oral cancers, and an anti-HER2 mAb (H2Mab-19) demonstrated antitumor activity (45). Therefore, anti-HER2 therapies using trastuzumab could be effective for the treatment of oral cancers. HER2 expression was reported in only 1.4% of immunohistochemical analyses of oral cancer (46), although it is expressed in 10.4% of breast cancers (47). Therefore, targeting only HER2 may be insufficient for conquering oral cancers. As antitumor effects of combined gefitinib and trastuzumab or cetuximab and trastuzumab treatment on head and neck SCC (HNSCC) were demonstrated in vitro (48,49), those few oral cancer patients displaying HER2 overexpression/amplification may possibly benefit from anti-HER2 therapy.
Furthermore, we previously investigated whether podocalyxin (PODXL) may be a therapeutic target in OSCC using anti-PODXL mAbs (50). We engineered an anti-PODXL mAb of IgG1 subclass (PcMab-47) into a mouse IgG2a-type mAb (47-mG2a) to increase ADCC. We further developed 47-mG2a-f, a core fucose-deficient variant of 47-mG2a to further augment its ADCC. In vivo analysis revealed that 47-mG2a-f, but not 47-mG2a, exhibited antitumor activity in SAS and HSC-2 ×enograft models at a dose of 100 µg/mouse/week administered three times. Although both 47-mG2a and 47-mG2a-f exhibited antitumor activity in HSC-2 ×enograft models at a dose of 500 µg/mouse/week administered twice, 47-mG2a-f also demonstrated higher antitumor activity than 47-mG2a, indicating that a core fucose-deficient anti-PODXL mAb could be useful for antibody-based therapy against PODXL-expressing OSCCs. Therefore, we used the core-fucose-deficient anti-CD44 mAb (5-mG2a-f) for treating CD44-expressing oral cancers.
In this study, we demonstrated that 5-mG2a-f exerts ADCC/CDC activities in vitro, and antitumor activities in vivo. Importantly, 5-mG2a-f effectively reduced the growth of SAS and HSC-2 ×enografts, even when 5-mG2a-f was injected 7 days after cell implantations into the mice. However, tumor volume reduction of SAS and HSC-2 on day 27 by 5-mG2a-f was still only 43 and 32%, respectively, indicating that anti-CD44 therapy might not be robust enough for conquering most oral cancers. One potential reason for this weak antitumor activity is the lower ADCC activity and CDC activity of 5-mG2a-f, despite high binding activity in SAS cells (KD: 2.8×10−10 M) and HSC-2 cells (KD: 2.6×10−9 M).
In our previous report, C44Mab-5 detected CD44s (27). Although the binding epitope of C44Mab-5 may potentially be located between exon-1 and exon-5, we have not been able to determine the exact binding epitope of C44Mab-5, likely because C44Mab-5 recognizes the tertiary structure of CD44 rather simple peptides or glycans. Because the binding epitope is critical for ADCC/CDC activities of mAbs, other anti-CD44 mAbs of various epitopes will need to be developed in future studies.
Targeting multiple targets, such as EGFR, HER2, PODXL, and CD44 may be needed for effective therapy to conquer oral cancers. Another important goal is the targeting of cancer-specific antigens using a cancer-specific mAb (CasMab) because EGFR, HER2, PODXL, and CD44 are widely expressed in normal tissues. We previously established CasMab against podoplanin (PDPN), which is expressed in many cancers, including oral cancers (51–54). In xenograft models with HSC-2 cells, a mouse-human chimeric mAb, chLpMab-23, exerted antitumor activity using human natural killer cells, indicating that chLpMab-23 may be useful for antibody therapy against PDPN-expressing oral cancers (54). In the future study, cancer-specific anti-CD44 mAbs may also be developed that can reduce the adverse effects of traditional antibody therapy.
Supplementary Material
Supporting Data
Acknowledgements
We thank Ms. Saori Handa and Mr. Yu Komatsu (Department of Antibody Drug Development, Tohoku University Graduate School of Medicine) for technical assistance concerning the in vitro experiments, and Ms. Akiko Harakawa [Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation] for technical assistance regarding the animal experiments.
Funding
This research was supported in part by Japan Agency for Medical Research and Development (AMED) under grant nos. JP20am0401013 (YK), JP20am0101078 (YK), and JP20ae0101028 (YK), and by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI) grant nos. 17K07299 (MKK), 19K07705 (YK), and 20K16322 (MS).
Availability of data and materials
The datasets used and/or analyzed during the study are available from the corresponding author on reasonable request.
Authors' contributions
HHo, JT, TO, TN, MS, TA, YS, and MY performed the experiments. MKK analyzed the experimental data. MK, HHa, and YK designed the current study and wrote the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Ethics approval and consent to participate
Animal studies for ADCC and the antitumor activity were approved by the Institutional Committee for Experiments of the Institute of Microbial Chemistry (Numazu-shi, Shizuoka, Japan) (permit no. 2020-003).
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Glossary
Abbreviations
Abbreviations:
AAL |
Aleuria aurantia lectin |
ABTU |
Antibody Bank of Tohoku University |
ADCC |
antibody-dependent cellular cytotoxicity |
ATCC |
American Type Culture Collection |
BSA |
bovine serum albumin |
CasMab |
cancer-specific mAb |
CBIS |
cell-based immunization and screening |
CDC |
complement-dependent cytotoxicity |
CD44s |
CD44 standard |
CD44v |
CD44 variant |
CHO |
Chinese hamster ovary |
Con A |
concanavalin A |
DMEM |
Dulbecco's modified Eagle's medium |
EDTA |
ethylenediaminetetraacetic acid |
ELISA |
enzyme-linked immunosorbent assay |
FBS |
fetal bovine serum |
FDA |
Food and Drug Administration |
FGF |
fibroblast growth factor |
HNSCC |
head and neck squamous cell carcinoma |
HB-EGF |
heparin-binding epidermal growth factor |
JCRB |
Japanese Collection of Research Bioresources Cell Bank |
mAb |
monoclonal antibody |
OSCC |
oral squamous cell carcinoma |
PBS |
phosphate-buffered saline |
PDPN |
podoplanin |
PhoSL |
Pholiota squarrosa lectin |
PODXL |
podocalyxin |
PVDF |
polyvinylidene difluoride |
RTKs |
receptor tyrosine kinases |
RT-PCR |
reverse transcription-polymerase chain reaction |
SCC |
squamous cell carcinoma |
SDS |
sodium dodecyl sulfate |
SEM |
standard error of the mean |
VEGFR |
vascular endothelial growth factor receptor |
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, et al: Interaction between tobacco and alcohol use and the risk of head and neck cancer: Pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev. 18:541–550. 2009. View Article : Google Scholar : PubMed/NCBI | |
Tota JE, Anderson WF, Coffey C, Califano J, Cozen W, Ferris RL, St John M, Cohen EE and Chaturvedi AK: Rising incidence of oral tongue cancer among white men and women in the United States, 1973–2012. Oral Oncol. 67:146–152. 2017. View Article : Google Scholar : PubMed/NCBI | |
Hussein AA, Helder MN, de Visscher JG, Leemans CR, Braakhuis BJ, de Vet HCW and Forouzanfar T: Global incidence of oral and oropharynx cancer in patients younger than 45 years versus older patients: A systematic review. Eur J Cancer. 82:115–127. 2017. View Article : Google Scholar : PubMed/NCBI | |
Sherman L, Sleeman J, Herrlich P and Ponta H: Hyaluronate receptors: Key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol. 6:726–733. 1994. View Article : Google Scholar : PubMed/NCBI | |
Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H, Savani RC and Kumar S: Hyaluronan-mediated angiogenesis in vascular disease: Uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol. 26:58–68. 2007. View Article : Google Scholar : PubMed/NCBI | |
Rodrigo JP, Dominguez F, Alvarez C, Gonzalez MV, Herrero A and Suárez C: Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx. Am J Clin Pathol. 118:67–72. 2002. View Article : Google Scholar : PubMed/NCBI | |
Zöller M: CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 11:254–267. 2011. View Article : Google Scholar : PubMed/NCBI | |
Greenfield B, Wang WC, Marquardt H, Piepkorn M, Wolff EA, Aruffo A and Bennett KL: Characterization of the heparan sulfate and chondroitin sulfate assembly sites in CD44. J Biol Chem. 274:2511–2517. 1999. View Article : Google Scholar : PubMed/NCBI | |
Skelton TP, Zeng C, Nocks A and Stamenkovic I: Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol. 140:431–446. 1998. View Article : Google Scholar : PubMed/NCBI | |
Hofmann M, Rudy W, Zöller M, Tölg C, Ponta H, Herrlich P and Günthert U: CD44 splice variants confer metastatic behavior in rats: Homologous sequences are expressed in human tumor cell lines. Cancer Res. 51:5292–5297. 1991.PubMed/NCBI | |
Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 65:13–24. 1991. View Article : Google Scholar : PubMed/NCBI | |
Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Héroult M, Augustin HG, Ponta H and Orian-Rousseau V: A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood. 114:5236–5244. 2009. View Article : Google Scholar : PubMed/NCBI | |
Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P and Ponta H: Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell. 18:76–83. 2007. View Article : Google Scholar : PubMed/NCBI | |
Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P and Ponta H: CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16:3074–3086. 2002. View Article : Google Scholar : PubMed/NCBI | |
Rudy W, Hofmann M, Schwartz-Albiez R, Zöller M, Heider KH, Ponta H and Herrlich P: The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each one individually suffices to confer metastatic behavior. Cancer Res. 53:1262–1268. 1993.PubMed/NCBI | |
Jackson DG, Bell JI, Dickinson R, Timans J, Shields J and Whittle N: Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol. 128:673–685. 1995. View Article : Google Scholar : PubMed/NCBI | |
Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman G and Aruffo A: CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol. 128:687–698. 1995. View Article : Google Scholar : PubMed/NCBI | |
Hu S, Wu X, Zhou B, Xu Z, Qin J, Lu H, Lv L, Gao Y, Deng L, Yin J and Li G: IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 140:883–893. 2014. View Article : Google Scholar : PubMed/NCBI | |
Auvinen P, Tammi R, Kosma VM, Sironen R, Soini Y, Mannermaa A, Tumelius R, Uljas E and Tammi M: Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer. 132:531–539. 2013. View Article : Google Scholar : PubMed/NCBI | |
Fang YJ, Zhang L, Wu XJ, Lu ZH, Li JB, Ou QJ, Zhang MF, Ding PR, Pan ZZ and Wan DS: Impact of ERβ and CD44 expression on the prognosis of patients with stage II colon cancer. Tumour Biol. 33:1907–1914. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kokko LL, Hurme S, Maula SM, Alanen K, Grénman R, Kinnunen I and Ventelä S: Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol. 47:510–516. 2011. View Article : Google Scholar : PubMed/NCBI | |
Nguyen VN, Mirejovský T, Melinová L and Mandys V: CD44 and its v6 spliced variant in lung carcinomas: Relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma. 47:400–408. 2000.PubMed/NCBI | |
Ghatak S, Misra S and Toole BP: Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem. 277:38013–38020. 2002. View Article : Google Scholar : PubMed/NCBI | |
Marangoni E, Lecomte N, Durand L, de Pinieux G, Decaudin D, Chomienne C, Smadja-Joffe F and Poupon MF: CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer. 100:918–922. 2009. View Article : Google Scholar : PubMed/NCBI | |
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F and Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 12:1167–1174. 2006. View Article : Google Scholar : PubMed/NCBI | |
Yamada S, Itai S, Nakamura T, Yanaka M, Kaneko MK and Kato Y: Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5. Biochem Biophys Rep. 14:64–68. 2018.PubMed/NCBI | |
Kato Y, Mizuno T, Yamada S, Nakamura T, Itai S, Yanaka M, Sano M and Kaneko MK: Establishment of P38Bf, a core-fucose-deficient mouse-canine chimeric antibody against dog podoplanin. Monoclon Antib Immunodiagn Immunother. 37:218–223. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kilkenny C, Browne WJ, Cuthill IC, Emerson M and Altman DG: Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol. 8:e10004122010. View Article : Google Scholar : PubMed/NCBI | |
Aske KC and Waugh CA: Expanding the 3R principles: More rigour and transparency in research using animals. EMBO Rep. 18:1490–1492. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kobayashi Y, Tateno H, Dohra H, Moriwaki K, Miyoshi E, Hirabayashi J and Kawagishi H: A novel core fucose-specific lectin from the mushroom Pholiota squarrosa. J Biol Chem. 287:33973–33982. 2012. View Article : Google Scholar : PubMed/NCBI | |
Takei J, Kaneko MK, Ohishi T, Kawada M, Harada H and Kato Y: A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Oncol Lett. 19:2809–2816. 2020.PubMed/NCBI | |
Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, et al: Antiglycopeptide mouse monoclonal antibody LpMab-21 exerts antitumor activity against human podoplanin through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Monoclon Antib Immunodiagn Immunother. 36:20–24. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wimmerova M, Mitchell E, Sanchez JF, Gautier C and Imberty A: Crystal structure of fungal lectin: Six-bladed beta-propeller fold and novel fucose recognition mode for Aleuria aurantia lectin. J Biol Chem. 278:27059–27067. 2003. View Article : Google Scholar : PubMed/NCBI | |
Sumner JB, Howell SF and Zeissig A: Concanavalin a and Hemagglutination. Science. 82:65–66. 1935. View Article : Google Scholar : PubMed/NCBI | |
Rivera C: Essentials of oral cancer. Int J Clin Exp Pathol. 8:11884–11894. 2015.PubMed/NCBI | |
Güneri P and Epstein JB: Late stage diagnosis of oral cancer: Components and possible solutions. Oral Oncol. 50:1131–1136. 2014. View Article : Google Scholar : PubMed/NCBI | |
Vokes EE: Induction chemotherapy for head and neck cancer: Recent data. Oncologist. 15 (Suppl 3):S3–S7. 2010. View Article : Google Scholar | |
Marcazzan S, Varoni EM, Blanco E, Lodi G and Ferrari M: Nanomedicine, an emerging therapeutic strategy for oral cancer therapy. Oral Oncol. 76:1–7. 2018. View Article : Google Scholar : PubMed/NCBI | |
Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, Macluskey M, Chan KK and Conway DI: Interventions for the treatment of oral cavity and oropharyngeal cancer: Chemotherapy. Cochrane Database Syst Rev. 2011:CD0063862011. | |
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI | |
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI | |
Naruse T, Yanamoto S, Matsushita Y, Sakamoto Y, Morishita K, Ohba S, Shiraishi T, Yamada SI, Asahina I and Umeda M: Cetuximab for the treatment of locally advanced and recurrent/metastatic oral cancer: An investigation of distant metastasis. Mol Clin Oncol. 5:246–252. 2016. View Article : Google Scholar : PubMed/NCBI | |
Amit M, Yen TC, Liao CT, Chaturvedi P, Agarwal JP, Kowalski LP, Ebrahimi A, Clark JR, Kreppel M, Zöller J, et al: Improvement in survival of patients with oral cavity squamous cell carcinoma: An international collaborative study. Cancer. 119:4242–4248. 2013. View Article : Google Scholar : PubMed/NCBI | |
Takei J, Kaneko MK, Ohishi T, Kawada M, Harada H and Kato Y: H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts. Exp Ther Med. 20:846–853. 2020. View Article : Google Scholar : PubMed/NCBI | |
Hanken H, Gaudin R, Gröbe A, Fraederich M, Eichhorn W, Smeets R, Simon R, Sauter G, Grupp K, Izbicki JR, et al: Her2 expression and gene amplification is rarely detectable in patients with oral squamous cell carcinomas. J Oral Pathol Med. 43:304–308. 2014. View Article : Google Scholar : PubMed/NCBI | |
Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z and Kurzrock R: HER2 expression status in diverse cancers: Review of results from 37,992 patients. Cancer Metastasis Rev. 34:157–164. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kondo N, Ishiguro Y, Kimura M, Sano D, Fujita K, Sakakibara A, Taguchi T, Toth G, Matsuda H and Tsukuda M: Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncol Rep. 20:373–378. 2008.PubMed/NCBI | |
Kondo N, Tsukuda M, Sakakibara A, Takahashi H, Hyakusoku H, Komatsu M, Niho T, Nakazaki K and Toth G: Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines. Int J Oncol. 40:1805–1812. 2012.PubMed/NCBI | |
Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, et al: Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. Oncotarget. 9:22480–22497. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kato Y and Kaneko MK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep. 4:59242014. View Article : Google Scholar : PubMed/NCBI | |
Yamada S, Ogasawara S, Kaneko MK and Kato Y: LpMab-23: A cancer-specific monoclonal antibody against human podoplanin. Monoclon Antib Immunodiagn Immunother. 36:72–76. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S and Kato Y: Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. Cancer Med. 6:768–777. 2017. View Article : Google Scholar : PubMed/NCBI | |
Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, et al: ChLpMab-23: Cancer-specific human-mouse chimeric anti-podoplanin antibody exhibits antitumor activity via antibody-dependent cellular cytotoxicity. Monoclon Antib Immunodiagn Immunother. 36:104–112. 2017. View Article : Google Scholar : PubMed/NCBI |